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INTRODUCTION:  Large  cell neuroendocrine  carcinoma  (LCNEC)  of  the endometrium  is  a rare  malignancy
with  an  aggressive  course.  Although  data  is  limited  to  case  reports,  the  prognosis  appears  to be poor,
similar  to  other  type  II uterine  cancers.  A  total of 12  cases  of  LCNEC  of  the  uterus  have  been published  to
date.
PRESENTATION  OF  CASE:  A  71  year-old  woman  presented  with  postmenopausal  vaginal  bleeding.  Endome-
trial  biopsy  was non-diagnostic  for LCNEC.  She  underwent  surgical  debulking  and  staging  of  a  22 cm
endometrial  tumor  with  omental  metastasis  and  positive  lymph  nodes.  Her  ﬁnal  FIGO  stage  was  IVB.
DISCUSSION: We  summarize  all prior  case  reports  of LCNEC  of  the  endometrium  and discuss  the deﬁni-
tion,  presentation,  imaging  and  surgical  management.  The  pathology  with  immunohistochemical  review,
adjuvant  therapy  and prognosis  of  LCNEC  of  the  endometrium  are  also  reviewed.D56 CONCLUSION: Pathologic  ﬁndings  and immunohistochemistry  are  essential  in  making  a  diagnosis  of
LCNEC  of  the  endometrium.  Primary  debulking  and  surgical  staging  is  typically  performed,  but  if  a
diagnosis  of  LCNEC  can  be  made  preoperatively  with  immunohistochemistry,  surgeons  should  consider
neoadjuvant  chemotherapy  due  to  its high  grade  histology  and aggressive  course.  Otherwise  adjuvant
chemotherapy  is usually  given.  Even  with  early  stage  disease,  the  prognosis  seems  poor.  Due  to the  rarity
of  this  aggressive  malignancy,  more  data  is needed  to  establish  incidence.
gical© 2013 Sur  
. Introduction
Large cell neuroendocrine carcinoma (LCNEC) of the
ndometrium is a rare malignancy with an aggressive course.
lthough data is limited to case reports, the prognosis appears
o be poor, similar to other type II uterine cancers. A total of
2 cases of LCNEC of the uterus, not including ours, have been
ublished in the English literature (Table 1).1–7 Here we  discuss
he clinical course of a 71 year-old woman with widely metastatic
isease.. Case presentation
A 71 year-old Caucasian female, with a BMI  of 44, presented
ith her ﬁrst episode of postmenopausal vaginal bleeding. She
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underwent an endometrial biopsy which revealed extensive necro-
sis and apoptosis. Tumor cells were diffusely positive for vimentin,
desmin, and Ki67, while negative for AE1/AE3, CD10 and SMA. The
differential diagnosis from biopsy included undifferentiated sar-
coma, poorly differentiated adenocarcinoma and malignant mixed
mullerian tumor.
MRI  revealed a uterus measuring 19.5 cm × 13.1 cm × 12.3 cm
with complete loss of usual myometrial architecture with increased
T2 signal at the inﬁltrative lesion (Fig. 1A–D). The mass appeared to
involve the entire myometrium and appeared to extend along the
right fallopian tube surrounding a 7.4 cm myoma  lying in the broad
ligament. The endometrial echo was  thickened to 3.5 cm contain-
ing heterogeneous debris. No deﬁnite extension to parametria was
seen on MRI. A 3.1 cm × 2.5 cm left external iliac lymph node was
enlarged along with a 1.9 cm × 2.4 cm paraaortic node, which both
appeared concerning for metastasis.
Two weeks later, the patient underwent an exploratory laparo-
tomy, radical hysterectomy, debulking of a retroperitoneal tumor,
Open access under CC BY-NC-ND license. bilateral salpingo-oophorectomy, pelvic and para-aortic lymph
node dissection, bilateral ureterolysis, omenectomy, and resection
of the posterior bladder wall with repair. Intraoperatively, a large
primary tumor approximately 25 cm in size extruded from the
-NC-ND license. 
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Table  1
Large  cell neuroendocrine tumor of the endometrium.
Case Year Author Age Surgery Stage Histology Treatment Immunoproﬁle
positivity
Outcome
(months)
1 2004 Erhan 52 TAH, BSO ICa Pure LCNEC RT, Cis, Eto NSE SNP DOD  3
2  2007 Mulvany 50 TAH, BSO,
OMY, LN
IIIC Pure LCNEC RT, Cis, Eto NSE SNP AWD  12
3  2007 Mulvany 80 TAH, BSO, LN ICa LCNEC + endometrioid NFT NSE CGA DOD  5
4  2007 Mulvany 77 TAH, BSO IIBa LCNEC + endometrioid RT NSE SNP CGA CD56 DOD  23
5  2007 Mulvany 79 TAH, BSO,
omental bx,
peritoneum
IIIA LCNEC + endometrioid RT NSE CGA CD56 AWD  2
6  2007 Mulvany 88 TAH, BSO, LN IIIC LCNEC + SCNEC
+ endometrioid
RT  NSE CGA CD56 AWD  1
7  2008 Albores-Saavedra 42 RH ICa Pure LCNEC Cis, Eto SNP CGA CD56 AWD  9
8  2010 Terada 40 TAH, BSO,
PLND, OMY
IB LCNEC + sarcomatoid None SNP CD56 AWD  16
9  2011 Deodhar 70 TAH, BSO, OMY  1B Pure LCNEC Cis, Eto SNP CGA CD56 AWD  6
10  2011 Shahibi 59 TAH, BSO, OMY,
PPALND,  APPY
IIIC2 Pure LCNEC Carbo, Taxol,
RT.
Doxil.
Cis,  Eto, Oct
NSE SNP CGA CD56 DOD  12
11  2012 Makihara 73 None IVB Pure LCNEC NFT NSE SNP CGA DOD  1
12  2012 Makihara 73 TAH, BSO,
OMY, PPALND
IIIC1 Pure LCNEC Cis, Iri SNP CGA CD56 AWD  13
13  2013 Present case 71 RH, BSO, OMY,
PPALND
IVB Pure LCNEC Planned Cis,
Eto,  Oct
SNP  CGA CD56 DOD  1
TAH = Total abdominal hysterectomy, BSO = Bilateral salpingoophorectomy, OMY  = Omentectomy, RH = Radical hysterectomy, PLND = Pelvic lymph node dissec-
tion, PPALND = Pelvic and paraaortic lymph node dissection, APPY = Appendectomy, RT = Radiotherapy, NFT = No further treatment, Cis = Cisplatin, Eto = Etoposide,
Carbo = Carboplatin, Oct = Octreotide, Doxil = Pegelated doxorubicin, Iri = Irinotecan, NSE = Neural-speciﬁc enolase, SNP = Synaptophysin, CGA = Chromogranin A, DOD = Dead
of  disease, AWD  = Alive with disease
a 1998 FIGO staging.
Fig. 1. Sagittal (A) and coronal (B) T2 weighted images without fat saturation
through  the pelvis demonstrates abnormal diffusely inﬁltrative high T2 signal
throughout  the myometrium with loss of the normal architecture. Rounded mass
lesions with decreased T2 signal within the myometrium represent leiomyomas.
Heterogeneous  signal within the endometrial canal is likely debris. Axial diffusion
weighted  images (C) and axial T2-weighted images with fat saturation (D) redemon-
strated diffusely inﬁltrative process with increased signal one restricted diffusion
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and C). Immunohistochemical stains conﬁrmed the diagnosis
of a large cell neuroendocrine carcinoma of the endometrium
(Table 2). Synaptophysin, chromogranin A (CGA), and CD56 were
diffusely and strongly positive neuroendocrine markers. P53 and
Table 2
IHC  proﬁle of present case.
Antibody Marker for Results
CK7 Cytokeratin 7 Negative
AE1/3 Cytokeratin AE-1/AE-3 cocktail Negative
EMA Epithelial membrane antigen Negative
CK8/18 CAM 5.2 Ck, LMW  Negative
VIMENTIN Vimentin Focal positive
CD10 CD10 Negative
SYN Synaptophysin Diffuse strongly positive
CHRO  Chromogranin Diffuse positive
CD56 CD56 Diffuse strongly positive
P53  Oncoprotein 70%; 3+
P16 Dysplastic epithelial cell 90%; 3+
ER Estrogen receptor Negative
PR Progesterone receptor 70%; 2+
S100 S100 Negative
HMB45 Human melanoma Focal positive
MYOGENIN Myogenin Negative
DESMIN Desmin Negativemages  suggestive of a hypercellular state restricting the motion of water molecules.
he process can be seen to extend along the broad ligament on the left surrounding
 broad ligament leiomyoma.
terus and involved the small bowel mesentery with bulky lymph
odes measuring up to 4 cm No gross residual disease was  noted at
he end of the procedure.
On  gross pathologic exam, the uterus weighed 2120 g and mea-
ured 22 cm in widest diameter. The endometrial cavity was  ﬁlledwith  necrotic-hemorrhagic material and showed a friable, polypoid
mass attached to the anterior fundus (Fig. 2A). The tumor involved
the full thickness of the myometrium as well as the cervix, bilat-
eral ovaries and tubes. The upper vagina and bilateral parametria
were also inﬁltrated by tumor and lymphovascular space invasion
was present. One of 18 pelvic lymph nodes and one of 13 paraaor-
tic lymph nodes were positive for metastasis. The omentum was
diffusely inﬁltrated by tumor. Her ﬁnal FIGO stage was  IVB due to
omental involvement.
Microscopically, the tumor was poorly differentiated (Fig. 2BCD45 CD45 Negative
CD3 T cell Negative
CD20 B cell Negative
CD138 Plasma cell Negative
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Fig. 2. (A) Uterus and cervix shows marked thickened, yellow-tan, ﬂeshy walls and a subserosal, calciﬁed nodule on the upper side. The endometrial cavity is ﬁlled with
necrotic and hemorrhagic debris. (B) Sheets of the tumor cells. H&E 100×. (C) Tumor ce
high  nuclear/cytoplasmic ratios, prominent nucleoli, and amphophillic cytoplasm. Numer
areas of necrosis. H&E 400×.
F
P
P
t
(
s
a
b
O
m
nig. 3. Positive immunohistochemical stains (Synaptophysin, Chromogranin, CD56,
53, P16 and PR).
16 revealed 70–90% staining with 3+ intensity, estrogen recep-
or (ER) was negative, progesterone receptor (PR) was  positive
Fig. 3).
Postoperatively, the patient’s course was complicated by a
uperﬁcial wound infection and separation. She was treated with
ntibiotics, discharged home, and was planned to receive com-
ination chemotherapy with etoposide, cisplatin and octreotide.
n the 32nd post-operative day, she expired due to recurrent
alignant ascites and acute renal failure secondary to her malig-
ancy.lls are arranged in sheets without a deﬁned border. Individual cells are large with
ous mitotic ﬁgures and apoptotic bodies are seen, as well as multiple, interspersed
3. Discussion
3.1. Deﬁnition
LCNEC is an extremely rare malignancy of the uterus, most often
found in the cervix and/or ovaries and more commonly of the small
cell neuroendocrine type. The WHO  deﬁnes small-cell carcinoma as
an undifferentiated carcinoma with cellular and nuclear features
which include small-sized cells, scant cytoplasm, hyperchromatic,
ﬁnely granular and molded nuclei and inconspicuous nuclei.4 In
contrast, large cell carcinoma is deﬁned as undifferentiated large
cells that lack cytologic and architectural features of small cell car-
cinoma and glandular or squamous differentiation.4 More simply,
LCNEC are deﬁned as malignant tumors composed of large cells
that show neuroendocrine differentiation.6 All reported large cell
carcinomas of the uterus have contained neuroendocrine features.
3.2. Presentation
The median age at diagnosis for all cases of endometrial LCNEC
is 71 years (range 40–88 years). In the current case, the 71-year
old patient presented with postmenopausal vaginal bleeding as
was common among all prior reports. On endometrial sampling,
the biopsy was not suggestive of a neuroendocrine carcinoma;
the usual differential diagnosis for such a specimen includes type
2 tumors such as undifferentiated carcinoma or mesenchymal
tumors such as sarcoma or mixed mullerian tumor based on
immunohistochemical staining.
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.3. Imaging
Preoperatively, imaging was obtained to evaluate for metastatic
isease. Preoperative MRI, performed without intravenous gadolin-
um secondary to the patient’s renal function, demonstrated diffuse
bnormal inﬁltrative myometrial signal throughout the uterus with
oss of the normal uterine architecture. This diffusely inﬁltrative
rocess extended along the broad ligament to the left adnexa
nd demonstrated restricted diffusion suggestive of a hypercel-
ular process. Conglomerate right external iliac lymphadenopathy
nd paraaortic lymphadenopathy also with restricted diffusion was
resent. These ﬁndings were suggestive of a uterine sarcoma.
In  another report by Makihara et al., the MRI  ﬁndings of LCNEC
eem to mimic  MRI  ﬁndings found in other poorly differentiated
ndometrial adenocarcinomas and uterine sarcomas.7 A gyneco-
ogic exam, endometrial sampling and MRI  should be included in
he initial workup of a suspected uterine LCNEC.
.4. Surgical management
The  most common initial management of LCNEC is cytore-
uctive surgery, based on prior published reports. Typically, a
ysterectomy and bilateral salpingo-ophorectomy are performed
t minimum. In one reported case where a biopsy conﬁrmed widely
etastatic disease, the patient did not undergo surgery and died.7
 post-mortem autopsy then conﬁrmed LCNEC of the uterus.7
lthough several case reports have noted an early stage at the time
f surgery, many of these patients went on to have distant metasta-
is and/or rapid recurrence. In cases where only TAH and BSO were
erformed without lymph node dissection, stage III disease may
ave been missed. Though there is no surgical standard for this
are histology, most patients will undergo hysterectomy presumed
igh grade sarcoma or carcinoma that is in fact LCNEC. If a LCNEC
an feasibly be diagnosed on a preoperative endometrial biopsy or
urettage specimen, providers may  want to consider neoadjuvant
herapy versus primary surgery as is done in advanced cases of
varian cancer. Although complete surgical staging with omentec-
omy and pelvic and paraaortic lymphadenectomy is required for
ccurate staging of uterine cancer, treating physicians may  want
o asses the patient’s response to chemotherapy ﬁrst, since surgery
as not been proven to be entirely beneﬁcial in most cases.
.5.  Pathology
Because LCNEC can sometimes be mixed with other histolog-
cal types, they can be easily dismissed as poorly differentiated
ndometrioid carcinomas and are likely underreported. Histogeni-
ally, LCNEC of the uterus most likely arises from neuroendocrine
ells of the endometrium.1 Grossly, the typical ﬁnding is a polypoid
ass conﬁned to the endometrium in stage 1 disease.1–5 The patho-
ogic features typically include high grade scant stroma, ulceration,
xtensive tumor necrosis, and a trabecular, organoid, palisading
r rosette-like growth pattern.1–3,5 In the majority of cases, the
ollowing cellular features of abundant cytoplasm with a granular
osinophilic or basophilic appearance, large nuclei, small but fre-
uent nucleoli and mitotic rates > 10 per 10 HPF were observed.1–7
.6. Immunoproﬁle
The most useful tool for diagnosing uterine LCNEC is the
mmunohistochemical proﬁle. Neuroendocrine differentiation in
CNEC of the uterus can be conﬁrmed by staining for synapto-
hysin, chromogranin and CD56. A summary of previous reports
uggests that two of the three tumor markers may  conﬁrm
 diagnosis of LCNEC. Cervical LCNEC may  express neuroen-
ocrine markers with approximately 25 to 38% of cases expressingPEN  ACCESS
 Surgery Case Reports 4 (2013) 651– 655
chromogranin and synpatophysin.9–12 In the present case, the
tumor was diffusely strongly positive for all three markers. Ear-
lier case reports suggest that neuron-speciﬁc enolase (NSE) may  be
a sensitive marker but may  not be as useful for diagnosis.1,2,7
3.7. Adjuvant therapy
In  previous reports on uterine LCNEC, adjuvant
chemotherapy1–3,5–7 and/or radiation1,2,6 was either performed or
planned. There is limited data to guide treatment for LCNEC of the
uterus or cervix. No prospective trials exist for uterine LCNEC or
even for SCNEC of the cervix. Currently there is no consensus as to
the optimal management of these tumors. Like LCNEC of the cervix,
LCNEC of the endometrium requires a multi-modality approach.
Most physicians will favor surgery, followed by chemother-
apy, radiation or both. The patient in this report was  optimally
debulked to no gross residual disease, but she still recurred within
one month of surgery and succumbed to her disease. Octreotide,
a synthetic somatostatin analog, was planned for the patient in
the present case. Two other case reports have reported its use for
neuroendocrine tumors, one case demonstrating a partial response
and the other with progression of disease.6,13 Given this aggressive
course and poor prognosis, perhaps surgeons who  are able to
preoperatively diagnose LCNEC of the endometrium should con-
sider neoadjuvant chemotherapy and/or therapy with octreotide
prior to surgery. Platinum and Etoposide based chemotherapy
is generally used as adjuvant therapy, and this data is largely
extrapolated from SCNEC of the lung since data for cervical and
uterine neuroendocrine tumors is limited.14
3.8. Prognosis
Even for early stages, LCNEC of the endometrium appears to have
an aggressive course with a strong propensity for distant metastasis
and rapid recurrence. No prognostic data is available for LCNEC of
the uterus or cervix. The best available survival data is from small
cell neuroendocrine carcinoma (SCNEC) of the cervix. One small,
retrospective study showed that the estimated 3-year progression
free survival (PFS) and overall survival (OS) rates for cervical SCNEC
were 22% and 30%, respectively8. The median time to progression
was 9.1 months and the extent of disease was the only signiﬁ-
cant prognostic factor.8 In the same study, patients who  received
platinum-based chemotherapy had both a 3-year recurrence-free
survival (RFS) and a 3-year overall survival (OS) of 83%.8 In patients
who did not receive chemotherapy, the RFS and OS  were 0% and
20%, respectively.8 In our review of all reported cases of uterine
LCNEC, six out of 13 patients died of their disease. Of these six,
only two  received chemotherapy and four were dead of disease
by ﬁve months, two  of whom were early stage (IC) at diagnosis
(Table 1). Of the seven patients who  are reported to be alive with
LCNEC, four received platinum-based chemotherapy, two received
radiotherapy only, and one received no further treatment (Table 1).
Of all 13 reported cases, eight patients presented with advanced
FIGO stage III or IV disease. Based upon these reported cases, there
may be some beneﬁt to chemotherapy in LCNEC. Again, providers
may consider administering neoadjuvant chemotherapy when a
preoperative diagnosis of uterine LCNEC is possible, given the poor
prognosis of the disease even after surgical debulking.
3.9. ClassiﬁcationEndometrial LCNEC is a rare entity which is often likely
under-reported and misdiagnosed. When LCNEC of the uterus
is diagnosed, whether treatment should proceed as suggested
in earlier reports is questionable. Although the data on LCNEC
 –  O
nal of
i
s
t
w
t
p
p
p
f
r
4
s
o
o
i
p
(
i
m
i
w
d
a
t
s
a
i
n
g
C
F
E
p
o
o
A
l
i
p
A
l
1
1
1
1
1
1CASE  REPORT
M.-L.T. Nguyen et al. / International Jour
s limited, endometrial LCNEC appears to behave very aggres-
ively, akin to type II uterine cancers. In brief, type II cancers of
he endometrium typically present in older-aged, postmenopausal
omen, are unrelated to unopposed estrogen, have P53 muta-
ions, have poorly-differentiated and non-endometrioid histology,
resent with stage 3 or 4 disease, and have an unfavorable
rognosis.15,16 All of the above were true of the patient in the
resent case. Most, if not all, of these same elements were also
ound in the 12 other cases of endometrial LCNEC listed in this
eview (Table 1).
.  Conclusion
The presentation of endometrial LCNEC can mimic  uterine
arcoma with postmenopausal or abnormal uterine bleeding. Pre-
perative imaging with MRI  can be useful in assessing the extent
f disease. Cytoreductive debulking and surgical staging is typ-
cally performed for diagnostic and staging accuracy. Common
athological ﬁndings and a typical immunohistochemistry proﬁle
synptophysin, chromogranin and CD56) are paramount in mak-
ng a diagnosis of uterine LCNEC. In theory, a diagnosis of LCNEC
ay be made preoperatively with immunohistochemistry. If this
s the case, surgeons may  consider neoadjuvant chemotherapy
ith etoposide and a platinum agent followed by surgical cytore-
uction. Adjuvant therapy should consist of a similar regimen,
lthough prognosis even with early stage disease and adjuvant
herapy appears to be poor. LCNEC of the endometrium behaves
imilarly to other type II uterine cancers and should be classiﬁed
s such. Due to the rarity of this aggressive malignancy, more data
s needed to establish incidence. Clinicians are urged to report any
ew cases and may  need to rely on case reports and reviews to
uide treatment.
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